

Synthesis of some pyridine, thiopyrimidine, and isoxazoline derivatives based on the pyrrole moiety

Mohamed A. A. Radwan · Eman M. H. Abbas

Received: 22 July 2008 / Accepted: 19 August 2008 / Published online: 27 September 2008
© Springer-Verlag 2008

Abstract Condensation of 2-acetylpyrrole with 5-methylfuran-2-carboxyaldehyde and 4-chlorobenzaldehyde in 20% NaOH give the corresponding 2-chalconylpyrroles. Some new 2-alkoxy-3-cyano-4,6-diarylpyridines were synthesized by condensation of chalcones with malono-nitrile, followed by cyclization in sodium alkoxide. The reactivity of chalcones towards nitrogen nucleophiles such as thiourea and hydroxylamine hydrochloride to provide thiopyrimidines and isoxazolines was investigated.

Keywords Pyrroles · Pyridines · Thiopyrimidine · Isoxazoline

Introduction

Pyrrole ring represent a subunit in a large and varied class of marine natural products possessing interesting and potentially useful pharmacological activities (e.g., lamellarins [1, 2], lukianols [3], ningalins [4], storniamides [5], arcylarubins [6], and polycitrins [7]) that exhibit remarkable biological properties such as hypolipidemic, [8] antimicrobial, [9] anti-inflammatory [10] and antitumour activity [11]. Other marine natural products possessing a 3,4-substituted pyrrole ring as a common structural subunit such as halitulin was found to be cytotoxic against several tumour cell lines (e.g., P-388, A-549, HT-29 and MEL-28)

[12]. Also, a large number of substituted pyridines have been maintained to have several biological activities [13–17]. Moreover, many biologically active compounds include thiopyrimidine [18–22] or isoxazoline [23–25] ring as a structural subunit have been reported. Guided by the above observations, and in continuation of our previous work in the direction of the synthesis of bioactive compounds [26–29], we report here a convenient synthesis of functionalized pyridine, thiopyrimidine and isoxazoline derivatives incorporating pyrrole moiety as a common structural subunit.

Results and discussion


Chemistry

Chalcones (1,3-diaryl-2-propen-1-ones) are interesting precursors and display interesting biological activities, including cytotoxic and anticancer properties [30–33]. Condensation of the starting compound, 2-acetyl pyrrole (**1**) with 5-methylfuran-2-carboxyaldehyde and 4-chlorobenzaldehyde in the presence of 20% NaOH solution at 60 °C for 6 h afforded the corresponding (*E*)-3-(5-methylfuran-2-yl)-1-(1*H*-pyrrol-2-yl)prop-2-en-1-one (**2a**) and (*E*)-3-(4-chlorophenyl)-1-(1*H*-pyrrol-2-yl)prop-2-en-1-one (**2b**), in a good yields (82 and 86%). The coupling constant (*J*) in the ¹H NMR spectrum of C2-H and C3-H of the isolated (**2a**, **2b**) are in the range of 15.8–16 Hz which are characteristic to (*E*)-isomer of chalcones (Scheme 1).

In the present work, new compounds containing 2-alkoxy-pyridine moieties have been designed for their biological activity, particularly for antitumor properties. It was reported that the reaction of chalcones with malono-nitrile and ethyl cyanoacetate in the presence of ammonium

M. A. A. Radwan (✉)
Applied Organic Chemistry Department,
National Research Centre, Dokki, Cairo, Egypt
e-mail: m1radwan@yahoo.com


E. M. H. Abbas
Department of Chemistry of Natural products,
National Research Centre, Dokki, Cairo, Egypt




Scheme 1

acetate and absolute ethanol afforded cyanopyridines in low yield [13]. In the same way, the preparation of 2-alkoxy cyanopyridines in good yields was reported via Michael addition of malononitrile to α,β -unsaturated carbonyl system [34]. Here in, 2-chalconylpyrroles (**2a**, **2b**) were condensed with malononitrile in either sodium ethoxide/ethanol or sodium methoxide/methanol to yield the corresponding 2-alkoxycyanopyridines **4a**, **4b** or **5a**, **5b** in a good yield (78 and 80% or 81 and 83%). The reaction proceeds through Michael addition of α,β -unsaturated ketones to the malononitrile to afford adduct **3** which undergoes a nucleophilic attack by alkoxide anion followed by cyclization and subsequent dehydration of the cyclized product leads to the 2-alkoxycyanopyridines **4a**, **4b** or **5a**, **5b** (Scheme 2). It was observed that the increase in the carbon number of alkoxy group caused much prolongation time of the reaction and relatively low yield. The structure of the 2-alkoxycyanopyridine compounds was established on the basis of its elemental analysis and spectral data. For example, the IR spectrum of compound **4a** showed the presence of an absorption peak at $2,255\text{ cm}^{-1}$ due to cyano stretching frequency and its ^1H NMR spectrum revealed a characteristic triplet and quartet signals at $\delta = 1.38$ and 4.59 due to methyl and methylene of the ester group, and singlet at $\delta = 7.76$ ppm due to pyridine proton. In addition, its mass spectrum revealed a peak at $m/z = 293$ corresponding to its molecular ion.

Condensation of **2a**, **2b** with diamine, namely, thiourea in refluxing ethanolic potassium hydroxide afforded 2-thiopyrimidine derivatives **6a**, **6b**, in a good yield (77 and 69%) (Scheme 3). The structure of the 2-thiopyrimidine derivatives was established on the basis of its elemental analysis and spectral data. For example, the IR




Scheme 2



Scheme 3

spectrum of compound **6a** showed the presence of absorption peaks at $3,250\text{--}3,360\text{ cm}^{-1}$ due to amino groups and at $1,215\text{ cm}^{-1}$ due to thione ($\text{C}=\text{S}$) group and its ^1H NMR spectrum revealed a characteristic two doublets at $\delta = 5.20$ and 7.41 due to thiopyrimidine (H-4 and H-5) and two singlets at 10.12 and 10.14 ppm due to 2 NH pyrimidine groups. In addition, its mass spectrum revealed a peak at $m/z = 259$ corresponding to its molecular ion.

Also, condensation of **2a**, **2b** with hydroxylamine hydrochloride in the presence of anhydrous sodium acetate in refluxing acetic acid yielded isoxazolines **7a**, **7b** in a good yield (69 and 73%) (Scheme 4). The structure of the isoxazoline derivatives was established on the basis of its elemental analysis and spectral data. For example, the ^1H NMR spectrum of compound **7a** revealed a characteristic



Scheme 4

signals at $\delta = 1.65$, 1.80 due to methylene and $\delta = 5.15$ ppm due to methine protons of isoxazoline ring. In addition, its mass spectrum revealed a peak at $m/z = 216$ corresponding to its molecular ion.

Experimental

Chemistry

Melting points were determined on a Gallenkamp melting point apparatus. IR spectra were recorded on Shimadzu FT-IR 8101 PC infrared spectrophotometer. ^1H NMR spectra were recorded on a Jeol EX-270 MHz spectrometer using DMSO- d_6 or CDCl_3 as solvent and TMS as the internal standard. Mass spectra were recorded on a Finnigan SSQ 7000 GC-MS spectrometer. Microanalyses were performed at the Microanalytical Center of Cairo University and results agreed favorably with calculated values.

General procedure for the synthesis of 2-chalconylpyrroles

A mixture of 0.22 g 2-acetylpyrrole (**1**) (2 mmol) and 2 mmol of the appropriate aldehyde (**2a**: 5-methylfuran-2-carboxyaldehyde, **2b**: 4-chlorobenzaldehyde) in 30 cm^3 20% ethanolic NaOH was heated at 60 $^\circ\text{C}$ for 6 h. The reaction mixture was left to cool. The obtained solid was filtered off, air-dried, and crystallized from ethanol to give the corresponding chalcones **2a**, **2b**.

(E)-3-(5-Methylfuran-2-yl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one (**2a**, $\text{C}_{12}\text{H}_{11}\text{NO}_2$)

In 0.33 g (82%) yield; M.p.: 160–162 $^\circ\text{C}$ (ethanol); IR (KBr): $\bar{\nu} = 3271$ (NH), 1648 (C=O), 1596 (C=C) cm^{-1} ; ^1H NMR (270 MHz, DMSO- d_6): $\delta = 2.35$ (s, 3H, Me), 6.25 (dd, 1H, H-4, pyrrole, $J = 6.1$, 5.8 Hz), 6.30 (d, 1H, H-4, furan, $J = 6.8$ Hz), 6.85 (d, 1H, H-3, furan, $J = 6.8$ Hz), 7.12 (d, 1H, H-3, pyrrole, $J = 5.8$ Hz), 7.15 (d, 1H, H-5,

pyrrole, $J = 6.1$ Hz), 7.20 (d, 1H, H- α , $J = 15.8$ Hz), 7.42 (d, 1H, H- β , $J = 16$ Hz), 11.95 (br s, 1H, NH) ppm; MS (EI, 70 eV): $m/z = 201$ (M^+ , 100), 186 (63), 158 (38), 130 (37), 107 (6), 94 (27), 77 (18).

(E)-3-(4-Chlorophenyl)-1-(1H-pyrrol-2-yl)prop-2-en-1-one (**2b**)

In 0.4 g (86%) yield; M.p.: 158–160 $^\circ\text{C}$ (ethanol) (Ref. [35] 154–156 $^\circ\text{C}$).

General method for preparation of 2-alkoxy-3-cyano-4,6-diaryl pyridines

Compound **2a** or **2b** (2 mmol) were added during stirring to a freshly prepared sodium alkoxide solution (2 mmol of sodium in 20 cm^3 of each of absolute methanol or ethanol). Malononitrile (0.2 g, 3 mmol) was then added with continuous stirring at room temperature until the precipitate was separated out. The solid separated was collected by filtration and recrystallized from suitable solvent.

2-Ethoxy-4-(5-methylfuran-2-yl)-6-(1H-pyrrol-2-yl)pyridine-3-carbonitrile (**4a**, $\text{C}_{17}\text{H}_{15}\text{N}_3\text{O}_2$)

In 0.46 g (78%) yield; M.p.: 202 $^\circ\text{C}$ (DMF); IR (KBr): $\bar{\nu} = 3241$ (NH), 2,255 (CN) cm^{-1} ; ^1H NMR (270 MHz, DMSO- d_6): $\delta = 1.38$ (t, 3H, Me, $J = 6.7$ Hz), 2.37 (s, 3H, Me), 4.59 (q, 2H, CH_2 , $J = 6.7$ Hz), 6.23 (dd, 1H, H-4, pyrrole, $J = 5.9$, 5.6 Hz), 6.42 (d, 1H, H-4, furan, $J = 6.8$ Hz), 6.95 (d, 1H, H-3, furan, $J = 6.8$ Hz), 7.10 (d, 1H, H-3, pyrrole, $J = 5.6$ Hz), 7.4 (d, 1H, H-5, pyrrole, $J = 5.9$ Hz), 7.6 (s, 1H, H-5, pyridine), 11.75 (br s, 1H, NH) ppm; MS (EI, 70 eV): $m/z = 293$ (M^+ , 100), 278 (16), 265 (51), 236 (11), 194 (7), 179 (3), 132 (4).

4-(4-Chlorophenyl)-2-ethoxy-6-(1H-pyrrol-2-yl)pyridine-3-carbonitrile (**4b**, $\text{C}_{18}\text{H}_{14}\text{ClN}_3\text{O}$)

In 0.52 g (80%) yield; M.p.: 197 $^\circ\text{C}$; IR (KBr) (DMF/ H_2O): $\bar{\nu} = 3265$ (NH), 2,248 (CN), cm^{-1} ; ^1H NMR (270 MHz, DMSO- d_6): $\delta = 1.37$ (t, 3H, Me), 4.61 (q, 2H, CH_2), 6.26 (dd, 1H, H-4, pyrrole, $J = 5.7$, 6.1 Hz), 7.11 (d, 1H, H-3, pyrrole, $J = 5.7$ Hz), 7.45 (d, 1H, H-5, pyrrole, $J = 6.1$ Hz), 7.61 (d, 2H, $J = 7.8$ Hz, Ph), 7.72 (d, 2H, $J = 7.8$ Hz, Ph), 7.76 (s, 1H, H-5, pyridine), 11.84 (br s, 1H, NH) ppm; MS (EI, 70 eV): $m/z = 323$ (M^+ , 100), 294 (24), 278 (14), 243 (41), 229 (17), 217 (10), 194 (6), 131 (15), 113 (12), 91 (4), 77 (7).

2-Methoxy-4-(5-methylfuran-2-yl)-6-(1H-pyrrol-2-yl)pyridine-3-carbonitrile (**5a**, $\text{C}_{16}\text{H}_{13}\text{N}_3\text{O}_2$)

In 0.45 g (81%) yield; M.p.: 212 $^\circ\text{C}$ (AcOH); IR (KBr): $\bar{\nu} = 3265$ (NH), 2,242 (CN), cm^{-1} ; ^1H NMR (270 MHz, CDCl_3): $\delta = 2.41$ (s, 3H, Me), 4.05 (s, 3H, OMe), 6.17 (dd, 1H, H-4, pyrrole, $J = 5.6$, 5.8 Hz), 6.32 (d, 1H, H-4, furan, $J = 6.5$ Hz), 6.86 (d, 1H, H-3, furan, $J = 5.5$ Hz), 6.95 (d, 1H, H-3, pyrrole, $J = 5.6$ Hz), 7.48 (d, 1H, H-5, pyrrole,

$J = 5.8$ Hz), 7.51 (s, 1H, H-5, pyridine), 9.43 (br s, 1H, NH) ppm; MS (EI, 70 eV): $m/z = 279$ (M^+ , 34), 278 (100), 263 (59), 249 (73), 235 (71), 220 (75), 192 (79), 178 (68), 166 (54), 140 (69), 91 (83), 77 (58).

4-(4-Chlorophenyl)-2-methoxy-6-(1H-pyrrol-2-yl)pyridine-3-carbonitrile (5b), $C_{17}H_{12}ClN_3O$

In 0.51 g (83%) yield; M.p.: 266 °C (AcOH/H₂O); IR (KBr): $\bar{\nu} = 3278$ (NH), 2,240 (CN), cm^{-1} ; 1H NMR (270 MHz, CDCl₃): $\delta = 4.1$ (s, 3H, OMe), 6.3 (dd, 1H, H-4, pyrrole, $J = 5.9, 6.2$ Hz), 6.83 (d, 1H, H-3, pyrrole, $J = 5.9$ Hz), 7.1 (d, 1H, H-5, pyrrole, $J = 6.2$ Hz), 7.2 (s, 1H, H-5, pyridine), 7.45 (d, 2H, $J = 7.8$ Hz, Ph), 7.55 (d, 2H, $J = 7.8$ Hz, Ph), 9.5 (br s, 1H, NH) ppm; MS (EI, 70 eV): $m/z = 309$ (M^+ , 100), 293 (19), 278 (41), 243 (25), 220 (13), 217 (17), 114 (22), 91 (13), 77 (32).

General procedure for the synthesis 2-thiopyrimidine derivatives

Thiourea (0.076 g, 1 mmol) was added to 1 mmol of **2a**, **2b** in 50 cm³ ethanolic potassium hydroxide (1%). The reaction mixture was refluxed for 4–6 h and then poured gradually with stirring into cold water. The solid formed was filtered off, washed with H₂O, and crystallized from suitable solvent to give **6a**, **6b**.

3,4-Dihydro-4-(5-methylfuran-2-yl)-6-(1H-pyrrol-2-yl)pyrimidine-2(1H)-thione (6a), $C_{13}H_{13}N_3OS$

In 0.2 g (77%) yield; M.p.: 272 °C (ethanol/DMF); IR (KBr): $\bar{\nu} = 3,250$ – $3,260$ (3NH), 1215 (C=S) cm^{-1} ; 1H NMR (270 MHz, DMSO- d_6): $\delta = 2.43$ (s, 3H, Me), 5.20 (d, 1H, H-4, pyrimidine, $J = 5.4$ Hz), 6.11 (dd, 1H, H-4, pyrrole, $J = 5.7, 6.1$ Hz), 6.21 (d, 1H, H-4, furan, $J = 6.8$ Hz), 6.85 (d, 1H, H-3, furan, $J = 6.8$ Hz), 6.97 (d, 1H, H-3, pyrrole, $J = 5.7$ Hz), 7.35 (d, 1H, H-5, pyrrole, $J = 6.1$ Hz), 7.41 (dd, 1H, H-5, pyrimidine, $J = 5.4$ Hz), 9.43 (br s, 1H, NH, exchangeable with D₂O), 10.12, 10.14 (br 2s, 2H, 2NH-pyrimidine, exchangeable with D₂O) ppm; MS (EI, 70 eV): $m/z = 259$ (M^+ , 11), 239 (31), 211 (19), 187 (9), 109 (29), 98 (58), 83 (53), 71 (93), 56 (100).

4-(4-Chlorophenyl)-3,4-dihydro-6-(1H-pyrrol-2-yl)pyrimidine-2(1H)-thione (6b), $C_{14}H_{12}ClN_3S$

In 0.27 g (69%) yield; M.p.: 251 °C (ethanol/DMF); IR (KBr): $\bar{\nu} = 3249$ – 3356 (3NH), 1217 (C=S), cm^{-1} ; 1H NMR (270 MHz, DMSO- d_6): $\delta = 5.19$ (d, 1H, H-4, pyrimidine, $J = 5.2$ Hz), 6.14 (dd, 1H, H-4, pyrrole, $J = 5.8, 6.0$ Hz), 7.1 (d, 1H, H-3, pyrrole, $J = 5.8$ Hz), 7.27 (d, 1H, H-5, pyrrole, $J = 6.0$ Hz), 7.33 (dd, 1H, H-5, pyrimidine, $J = 5.2$ Hz), 7.35 (d, 2H, $J = 7.8$ Hz, Ph), 7.39 (d, 2H, $J = 7.8$ Hz, Ph), 9.51 (br s, 1H, NH, exchangeable with D₂O), 10.15, 10.21 (br 2s, 2H, 2NH-

pyrimidine, exchangeable with D₂O) ppm; MS (EI, 70 eV): $m/z = 389$ (M^+ , 17), 357 (13), 345 (31), 310 (24), 280 (16), 217 (37), 114 (27), 91 (15), 77 (38), 56 (100).

General procedure for the synthesis isoxazoline derivatives

A mixture of 1 mmol **2a**, **2b**, ~0.1 g hydroxylamine hydrochloride (1 mmol), and 0.082 g anhydrous sodium acetate (1 mmol) in 30 cm³ glacial acetic acid was heated under reflux for 6 h. The reaction mixture was cooled, poured into ice, the obtained solid was collected by filtration, washed with water, air dried, and crystallized from suitable solvent to give **7a**, **7b**.

4,5-Dihydro-5-(5-methylfuran-2-yl)-3-(1H-pyrrol-2-yl)isoxazole (7a), $C_{12}H_{12}N_2O_2$

In 0.15 g (69%) yield; M.p.: 213 °C (AcOH); IR (KBr): $\bar{\nu} = 3332$ (NH), 1586 (C=N) cm^{-1} ; 1H NMR (270 MHz, DMSO- d_6): $\delta = 1.65$ and 1.80 (m, CH₂-isoxazole), 2.41 (s, 3H, Me), 5.15 (m, CH-isoxazole), 6.13 (dd, 1H, H-4, pyrrole, $J = 5.7, 5.9$ Hz), 6.24 (d, 1H, H-4, furan, $J = 6.4$ Hz), 6.86 (d, 1H, H-3, furan, $J = 6.4$ Hz), 6.98 (d, 1H, H-3, pyrrole, $J = 5.7$ Hz), 7.3 (d, 1H, H-5, pyrrole, $J = 5.9$ Hz), 9.11 (br s, 1H, NH, exchangeable with D₂O) ppm; MS (EI, 70 eV): $m/z = 216$ (M^+ , 14), 185 (61), 170 (49), 109 (23), 98 (45), 83 (62), 71 (91), 56 (100).

5-(4-Chlorophenyl)-4,5-dihydro-3-(1H-pyrrol-2-yl)isoxazole (7b), $C_{13}H_{11}ClN_2O$

In 0.18 g (73%) yield; M.p.: 231 °C (AcOH); IR (KBr): $\bar{\nu} = 3311$ (NH), 1582 (C=N), cm^{-1} ; 1H NMR (270 MHz, DMSO- d_6): $\delta = 1.6$ and 1.83 (m, CH₂-isoxazole), 4.9 (m, CH-isoxazole), 6.14 (dd, 1H, H-4, pyrrole $J = 5.6, 5.9$ Hz), 7.13 (d, 1H, H-3, pyrrole $J = 5.7$ Hz), 7.33 (d, 1H, H-5, pyrrole $J = 5.9$ Hz), 7.37 (d, 2H, $J = 7.8$ Hz, Ph), 7.42 (d, 2H, $J = 7.8$ Hz, Ph), 9.51 (br s, 1H, NH, exchangeable with D₂O) ppm; MS (EI, 70 eV): $m/z = 246$ (M^+ , 32), 244 (69), 216 (9), 181 (12), 151 (36), 139 (13), 111 (27), 94 (100), 78 (30), 66 (41).

Acknowledgments We gratefully acknowledge the financial support of the National Research Centre (NRC), Dokki, Giza, Egypt.

References

- Gossauer A (2003) Prog Chem Org Nat Prod 86:1
- Bailly C (2004) Curr Med Chem Anti Cancer Agents 4:364
- Yoshida WY, Lee KK, Carrol AR, Scheuer PJ (1992) Helv Chim Acta 75:1721
- Kang H, Fenical W (1997) J Org Chem 62:3254
- Palermo JA, Brasco MFR, Seldes AM (1996) Tetrahedron 52:727
- Steglich W, Steffan B, Kopanski L, Eckhard G (1980) Angew Chem Int Ed Engl 19:459

7. Rudi A, Goldberg I, Stein Z, Frolov F, Benayahu Y, Schleyer M, Kashman Y (1994) *J Org Chem* 59:999
8. Chong PH, Seeger JD (1997) *Pharmacotherapy* 17:1157
9. Biava M, Fioravanti R, Porretta GC, Deidda D, Maullu C, Pompei R (1999) *Bioorg Med Chem Lett* 9:2983
10. Yee NK, Nummy LJ, Byrne DP, Smith LL, Roth GP (1998) *J Org Chem* 63:326
11. Pereira ER, Belin L, Sancelme M, Prudhomme M, Ollier M, Rapp M, Sevrè D, Riou J-F, Fabbro D, Meyer T (1996) *J Med Chem* 39:4471
12. Kashman Y, Koren-Goldshlager G, Gravalos MDG, Schleyer M (1999) *Tetrahedron Lett* 40:997
13. Attia A, Michael M (1982) *Pharmazie* 37:551
14. Yamada K, Takeda M, Wakuu L, Itoh N, Ohtsuka H, Tsunashima A, Wakuu TI (1982) *Chem Pharm Bull* 30:3197
15. Massimo P, Marco T, Daniela U, Giuseppe P, Pietro B, Fiorenzo P, Fabrizio Z (2000) *Il Farmaco* 55:669
16. Borgna P, Pregnolato M, Gamba IA, Mellerio G (1993) *J Heterocycl Chem* 30:1079
17. Maria GM, Valeria F, Daniele Z, Luciano V, Elena B (2001) *Il Farmaco* 56:587
18. Sierzputowska-Gracz H, Sochacka E, Malkiewicz A, Kuo K, Gehrke C, Agris PF (1987) *J Am Chem Soc* 109:7171
19. Sochacka E, Fratzak I (2004) *Tetrahedron Lett* 45:6729
20. Stoyanov S, Petkov I, Antonov L, Stoyanova T, Karagiannides P, Aslanidis P (1990) *Can J Chem* 68:1482
21. Hajos ZG, Kanojia RM, Press JB (1991) *Eur Pat Appl EP 458459 A2*; (1991) *Chem Abstr* 116:83701
22. Pathak AK, Pathak V, Seit LE, Sulng WJ, Reynolds RC (2004) *J Med Chem* 41:273
23. Conti P, Dallanoce C, De Amici M, De Micheli C, Klotz K-N (1998) *Bioorg Med Chem* 6:401
24. De Amici M, Conti P, Dallanoce C, Kassi L, Castellano S, Stefancich G, De Micheli C (2000) *Med Chem Res* 10:69
25. Dallanoce C, Meroni G, De Amici M, Hoffmann C, Klotz K-N, De Micheli C (2006) *Bioorg Med Chem* 14:4393
26. Fakhr IMI, Radwan MAA, El-Batran S, Abd El-Salam OM, El-Shenawy S (2008) *Eur J Med Chem* (in press)
27. Radwan MAA, Ragab EA, Sabry NM, El-Shenawy SM (2007) *Bioorg Med Chem* 15:3832
28. Radwan MAA, El-Sherbiny M (2007) *Bioorg Med Chem* 15:1206
29. Fakhr IMI, Hamdy NA, Radwan MAA, Ahmed YM (2004) *Egypt J Chem Special Issue (M. Kamel)*:201
30. Ducki S, Forrest R, Hadfield JA, Kendall Lawrence NJ, McGown AT, Rennison D (1998) *Biorg Med Chem Lett* 8:1051
31. Edwards ML, Stemerick DM, Sunkara PS (1990) *J Med Chem* 33:1948
32. Kumar SK, Hager E, Pettit C, Gurulingappa, Davidson NE, Khan SR (2003) *J Med Chem* 2813
33. Go ML, Wu X, Liu XL (2005) *Curr. Med Chem* 483
34. Al-Arab MM, Tabba HD, Abu-Yousef LA, Marilyn MO (1988) *Tetrahedron* 44:7293
35. Basaif SA, Sobahi AK, Hassan MA (2005) *Bull Korean Chem Soc* 26:1677